Clinical Trial Update: Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the relative bioavailability of a new formulation of NPT 2042 compared to the original formulation; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Epilepsy

Drugs mentioned

• NPT 2042

Snippet

Sponsor: NeuroPro Therapeutics, Inc. | Conditions: Epilepsy, Alzheimer Disease | Phase 1 | Status: COMPLETED